arrow
A

Antonio M. Risitano

Federico II University
H指数:67
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Publisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee

出版商更正:定义造血移植和细胞治疗领域的全球优先事项:EBMT全球委员会的一份声明文件

2026-10-120
OAAI
Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes harboring a paroxysmal nocturnal hemoglobinuria clone—a study on behalf of the Chronic Malignancies and Severe Aplastic Anemia Working Parties of the EBMT

异基因造血细胞移植治疗伴有阵发性睡眠性血红蛋白尿克隆异常的骨髓增生异常综合征——欧洲血液和骨髓移植学会慢性恶性病和重症再生障碍性贫血工作组代为研究

2026-08-130
PRE
Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global ComMittee

定义全球造血移植和细胞治疗的优先事项:EBMT全球委员会声明文件

2026-08-110
OAAI
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study

eltrombopag添加到标准免疫抑制治疗中作为一线疗法治疗重症再生障碍性贫血:EBMT-SAAWP RACE研究3期随机优越性研究的长期结果

2026-07-280
OAAI
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

2024年EBMT活动报告:完成一百万例HCT和2万例CAR-T。细胞疗法的重要里程碑

2026-05-270
OAAI
American Society of Hematology 2026 Guidelines for the Diagnosis and Management of Severe Acquired Aplastic Anemia

美国血液学学会2026年严重获得性再生障碍性贫血的诊断和管理指南

2026-04-010
OAAI
An extraction pipeline for analysis of hematopoietic stem cell transplantation data

一种用于分析造血干细胞移植数据的提取流程

2026-03-100
PRE
Allogeneic Hematopoietic Stem Cell Transplantation in ERCC6L2 Disease
2026-02-040
OAAI
Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report

造血干细胞移植对于实现再生障碍性贫血后髓系肿瘤的长期生存有效:欧洲血液和骨髓移植学会严重再生障碍性贫血报告

2026-01-010
OA
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies

一项针对接受二线治疗的难治/复发功能性高风险多发性骨髓瘤患者的意大利真实世界多中心研究

2025-09-100
OAAI
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

造血细胞移植和CAR-T在血液病、实体瘤和免疫紊乱中的适应证:2025年EBMT实践建议

2025-09-090
OAAI
Advancing the Integration of ‘Basic/Fundamental’ and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress

推进EBMT内“基础/根本”与转化细胞及基因治疗科学的整合:加速通往进步的路径

2025-08-070
PRE
Long-Term Outcome of Fanconi Anemia Patients From the Italian Registry on Behalf of the Marrow Failure Study Group of the AIEOP (Italian Association for Pediatric Haematology-Oncology)

法布里贫血患者长期结局:来自意大利注册登记系统,代表AIEOP(意大利儿科血液学-肿瘤学协会)骨髓衰竭研究组的研究

2025-06-060
OA
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors

口服iptacopan单药治疗阵发性夜间血红蛋白尿症:来自在抗C5治疗患者中进行的开放标签、随机、III期APPLY-PNH试验和既往未经补体抑制剂治疗的患者的开放标签、单臂、III期APPOINT-PNH试验的最终48周结果

2025-05-280
PRE
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates

门诊皮下注射 alemtuzumab 对于再生障碍性贫血是可行且安全的,并且与高缓解率相关。

2025-02-180
OA
Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

III期随机COMMODORE 2试验:Crovalimab在未接受补体抑制治疗的阵发性夜间血红蛋白尿(PNH)患者中的2年疗效与安全性

BLOOD
IF23.1
2024-11-050
PRE